Abstract Search

ea0070aep286 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Liraglutide and PYY_3–36 combination therapy partially achieves the metabolic benefits of Roux-en-Y gastric bypass surgery in diet-induced obese rats

Dischinger Ulrich , Hasinger Julia , Königsrainer Malina , Corteville Carolin , Otto Cristoph , Fassnacht Martin , Hankir Mohamed , Seyfried Florian

Background: Circulating levels of the appetite-suppressing and glucoregulatory gut hormones glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine 3–36 (PYY3–36) are markedly increased after Roux-en-Y gastric bypass surgery (RYGB), which may contribute to some of its profound metabolic benefits in morbidly obese individuals.Objectives: To directly compare the metabolic effects of chronic systemic administration of the clinic...

0 shares

Endocrine Abstracts

Liraglutide and PYY_3–36 combination therapy partially achieves the metabolic benefits of Roux-en-Y gastric bypass surgery in diet-induced obese rats

BiosciAbstracts

Endocrine Abstracts

Liraglutide and PYY3–36 combination therapy partially achieves the metabolic benefits of Roux-en-Y gastric bypass surgery in diet-induced obese rats

BiosciAbstracts

Liraglutide and PYY_3–36 combination therapy partially achieves the metabolic benefits of Roux-en-Y gastric bypass surgery in diet-induced obese rats